Literature DB >> 3818107

Penetration of ciprofloxacin into human lung tissue following intravenous injection.

D Schlenkhoff, A Dalhoff, J Knopf, W Opferkuch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3818107     DOI： 10.1007/bf01643967

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  7 in total

1.  Antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae. Report of a study group on bacterial resistance.

Authors:  A J Howard; C J Hince; J D Williams
Journal:  Br Med J       Date:  1978-06-24

2.  Single and multiple dose pharmacokinetics of ciprofloxacin.

Authors:  U Ullmann; W Giebel; A Dalhoff; P Koeppe
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Differences between bacteria grown in vitro and in vivo.

Authors:  A Dalhoff
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  Increase in antibiotic resistance in Haemophilus influenzae in the United Kingdom since 1977: report of study group.

Authors:  J Philpott-Howard; J D Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29

5.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  Tissue distribution of ciprofloxacin following oral and intravenous administration.

Authors:  A Dalhoff; H U Eickenberg
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

7.  Comparative in vitro studies with 4-quinolone antimicrobials.

Authors:  D Felmingham; M D O'Hare; M J Robbins; R A Wall; A H Williams; A W Cremer; G L Ridgway; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1985
  7 in total
  12 in total

1.  Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery.

Authors:  G Hopf; R Böcker; C J Estler; H J Radtke; W Floh
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 2.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

3.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

5.  Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.

Authors:  C A Hirata; D R Guay; W M Awni; D J Stein; P K Peterson
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Ciprofloxacin penetration into the pulmonary parenchyma in Japanese patients.

Authors:  Shuji Haraguchi; Masafumi Hioki; Koji Yamashita; Koan Orii; Yasuo Yamashita; Jun Kawamura; Mina Takushima; Naoya Endo; Kiyoshi Koizumi; Kazuo Shimizu
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

Review 7.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

Authors:  M J Haverkorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.